Research
Hormonal
Tirzepatide (Zepbound/Mounjaro) is associated with a higher proportion of 'super responders' (>15% weight loss) compared to semaglutide (Ozempic/Wegovy) in real-world settings.
If you are choosing between GLP-1 medications, tirzepatide (Zepbound/Mounjaro) may offer a higher probability of 'super response' (>15% weight loss) compared to semaglutide (Ozempic/Wegovy). However, individual response varies, and your specific health profile should guide the choice.
GoodSupportsHIGH confidence
Rates of super responders were highest for Zepbound (34%), followed by Wegovy (26%), Mounjaro (24%), and Ozempic (10%).
Why this rating
Large real-world cohort, but confounded by indication (different patient populations for different drugs).
Source
Decoding the hallmarks of GLP-1RA weight-loss super responders
AJ Venkatakrishnan et al. · Biology Methods and Protocols · 2025
DOI 10.1093/biomethods/bpag021
cohort · n=135349Cited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (semaglutide and tirzepatide) produce highly heterogeneous weight loss outcomes, with 'super responders' achieving >15% body weight loss while 'minimal responders' achieve <5%, driven by distinct pre-treatment clinical phenotypes rather than uniform biological response.Good
- Pre-treatment clinical phenotypes, specifically the presence or absence of certain comorbidities, are strongly associated with the likelihood of being a 'super responder' to specific GLP-1RA brands.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →